Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
- PMID: 33272316
- PMCID: PMC7712603
- DOI: 10.1186/s13071-020-04487-3
Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
Abstract
Background: The most common apicomplexan parasites causing bovine babesiosis are Babesia bovis and B. bigemina, while B. caballi and Theileria equi are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such as imidocarb diproprionate, but drug-resistant parasites are emerging, and alternative effective and safer drugs are needed. The endochin-like quinolones (ELQ)-300 and ELQ-316 have been proven to be safe and efficacious against related apicomplexans, such as Plasmodium spp., with ELQ-316 also being effective against Babesia microti, without showing toxicity in mammals.
Methods: The inhibitory effects of ELQ-300 and ELQ-316 were assessed on the growth of cultured B. bovis, B. bigemina, B. caballi and T. equi. The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of the ELQ compounds on the viability of horse and bovine peripheral blood mononuclear cells (PBMC) was assessed by monitoring cell metabolic activity using a colorimetric assay.
Results: We calculated the half maximal inhibitory concentration (IC50) at 72 h, which ranged from 0.04 to 0.37 nM for ELQ-300, and from 0.002 to 0.1 nM for ELQ-316 among all cultured parasites tested at 72 h. None of the parasites tested were able to replicate in cultures in the presence of ELQ-300 and ELQ-316 at the maximal inhibitory concentration (IC100), which ranged from 1.3 to 5.7 nM for ELQ-300 and from 1.0 to 6.0 nM for ELQ-316 at 72 h. Neither ELQ-300 nor ELQ-316 altered the viability of equine and bovine PBMC at their IC100 in in vitro testing.
Conclusions: The compounds ELQ-300 and ELQ-316 showed significant inhibitory activity on the main parasites responsible for bovine babesiosis and equine piroplasmosis at doses that are tolerable to host cells. These ELQ drugs may be viable candidates for developing alternative protocols for the treatment of bovine babesiosis and equine piroplasmosis.
Keywords: Babesia bigemina; Babesia bovis; Babesia caballi; Bovine babesiosis; ELQ-300; Endochin-like quinolones; Equine piroplamsosis; Theileria equi; nnELQ-316.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Assessment of Draxxin® (tulathromycin) as an inhibitor of in vitro growth of Babesia bovis, Babesia bigemina and Theileria equi.Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):265-270. doi: 10.1016/j.ijpddr.2018.04.004. Epub 2018 Apr 17. Int J Parasitol Drugs Drug Resist. 2018. PMID: 29689532 Free PMC article.
-
The effects of nitidine chloride and camptothecin on the growth of Babesia and Theileria parasites.Ticks Tick Borne Dis. 2018 Jul;9(5):1192-1201. doi: 10.1016/j.ttbdis.2018.04.019. Epub 2018 Apr 27. Ticks Tick Borne Dis. 2018. PMID: 29730263
-
Effects of dihydroorotate dehydrogenase (DHODH) inhibitors on the growth of Theileria equi and Babesia caballi in vitro.Exp Parasitol. 2017 May;176:59-65. doi: 10.1016/j.exppara.2017.03.002. Epub 2017 Mar 9. Exp Parasitol. 2017. PMID: 28286324
-
Review of equine piroplasmosis.J Vet Intern Med. 2013 Nov-Dec;27(6):1334-46. doi: 10.1111/jvim.12168. Epub 2013 Aug 28. J Vet Intern Med. 2013. PMID: 24033559 Review.
-
Comparative Bioinformatics Analysis of Transcription Factor Genes Indicates Conservation of Key Regulatory Domains among Babesia bovis, Babesia microti, and Theileria equi.PLoS Negl Trop Dis. 2016 Nov 10;10(11):e0004983. doi: 10.1371/journal.pntd.0004983. eCollection 2016 Nov. PLoS Negl Trop Dis. 2016. PMID: 27832060 Free PMC article. Review.
Cited by
-
In Vitro versus in Mice: Efficacy and Safety of Decoquinate and Quinoline-O-Carbamate Derivatives against Experimental Infection with Neospora caninum Tachyzoites.Pathogens. 2023 Mar 13;12(3):447. doi: 10.3390/pathogens12030447. Pathogens. 2023. PMID: 36986369 Free PMC article.
-
Identification of novel immune correlates of protection against acute bovine babesiosis by superinfecting cattle with in vitro culture attenuated and virulent Babesia bovis strains.Front Immunol. 2022 Nov 18;13:1045608. doi: 10.3389/fimmu.2022.1045608. eCollection 2022. Front Immunol. 2022. PMID: 36466866 Free PMC article.
-
Dual inhibition of the Echinococcus multilocularis energy metabolism.Front Vet Sci. 2022 Aug 5;9:981664. doi: 10.3389/fvets.2022.981664. eCollection 2022. Front Vet Sci. 2022. PMID: 35990276 Free PMC article.
-
Structure-activity relationships of Toxoplasma gondii cytochrome bc1 inhibitors.Expert Opin Drug Discov. 2022 Sep;17(9):997-1011. doi: 10.1080/17460441.2022.2096588. Epub 2022 Aug 8. Expert Opin Drug Discov. 2022. PMID: 35772172 Free PMC article.
-
Lactate Dehydrogenase as a Potential Therapeutic Drug Target to Control Babesia bigemina.Front Cell Infect Microbiol. 2022 Apr 19;12:870852. doi: 10.3389/fcimb.2022.870852. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35521220 Free PMC article.
References
-
- Florin-Christensen M, Suarez CE, Rodriguez AE, Flores DA, Schnittger L. Vaccines against bovine babesiosis: where we are now and possible roads ahead. Parasitol. 2014;1–30. 10.1017/S0031182014000961. - PubMed
MeSH terms
Substances
Grants and funding
- I01 BX001421/BX/BLRD VA/United States
- AI100569/NH/NIH HHS/United States
- I01 BX004522/BX/BLRD VA/United States
- I01 BX003312/BX/BLRD VA/United States
- R56 AI100569/AI/NIAID NIH HHS/United States
- BX004522/U.S. Department of Veterans Affairs (US)
- PR181134/U.S. Department of Defense
- 14S-RCS001/VA Research
- R01 AI141412/AI/NIAID NIH HHS/United States
- R01 AI100569/AI/NIAID NIH HHS/United States
- R01AI141412/National Institute of Allergy and Infectious Diseases
- IK2 BX002440/BX/BLRD VA/United States
- 108525-001/International Development Research Centre
- IK6 BX004857/BX/BLRD VA/United States
- 2090-32000-039-00D/Agricultural Research Service
- BX002440/U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development
- i01 BX003312/BX/BLRD VA/United States
LinkOut - more resources
Full Text Sources
Miscellaneous
